Viscosupplementation Market by Product (Five Injection, Single Injection, Three Injection), Source (Animal, Non-animal), Application, End-use - Global Forecast 2024-2030

Viscosupplementation Market by Product (Five Injection, Single Injection, Three Injection), Source (Animal, Non-animal), Application, End-use - Global Forecast 2024-2030

The Viscosupplementation Market size was estimated at USD 2.83 billion in 2023 and expected to reach USD 3.01 billion in 2024, at a CAGR 6.19% to reach USD 4.32 billion by 2030.

Viscosupplementation is a medical procedure involving the injection of hyaluronic acid into a joint, such as the knee, to relieve pain caused by conditions such as osteoarthritis. As a non-surgical treatment option, viscosupplementation aims to improve joint function, reduce pain, and possibly delay joint replacement surgery. Increasing incidences of joint disorders and sport-related injuries, a growing elderly population that is more susceptible to such ailments, and the rising preference for minimally invasive procedures significantly contribute to market growth. However, the existence of alternative treatment options, including steroid injections and non-pharmacologic therapies, may impede market growth. Nevertheless, technological advancements in formulating and delivering hyaluronic acid and healthcare infrastructure improvements are expected to create potential opportunities for developing the viscosupplementation market.

Regional Insights

The market is evolving in the Americas owing to the growing incidence of osteoarthritis, high healthcare expenditure, increasing preference for minimally invasive procedures, and widespread availability of several FDA-approved HA products. Advanced healthcare systems, increased awareness about osteoarthritis treatment options, and supportive regulatory frameworks are encouraging the growth of the viscosupplementation market in Europe. The Middle East and Africa viscosupplementation market is growing with improving availability and affordability of treatment and the prevalence of competitive treatment modalities for osteoarthritis. The Asia Pacific region represents significant demand for viscosupplementation due to high osteoarthritis prevalence, expanding healthcare infrastructure, and increasing accessibility to advanced osteoarthritis treatments. Besides, ongoing research to improve the efficacy of viscosupplementation therapy is anticipated to propel the demand for the viscosupplementation market globally.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Viscosupplementation Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

• Growing Need for Non-Surgical Treatment for Osteoarthritis
• Rising Occurrence of Lifestyle-Induced Disorders with Changing Eating Habits
• Surge in Geriatric Population and Obesity Globally

Market Restraints

• Side Effects and High Cost of The Hyaluronic Acid-Based Treatment

Market Opportunities

• Ongoing Advancements in the Development of Hyaluronic Acid-Based Therapies
• Extending Role of Viscosupplementation in Patellar Chondropathy

Market Challenges

• Strict Regulatory Mandates for Approval and Short Duration of Lubrication and Pain Relief

Market Segmentation Analysis

• Products: Burgeoning adoption of a three-injection regimen to reduce pain and enhance mobility in patients with osteoarthritis
• Source: Growing preference for non-animal-based hyaluronic acid as it eliminates hypersensitivity reaction risks
• Applications: Evolving applications of viscosupplementation treatment for knee osteoarthritis
• End-use: Proliferating utilization of viscosupplementation treatment in orthopedic clinics/ambulatory surgical centers (ASCs)

Market Disruption Analysis

• Porter’s Five Forces Analysis
• Value Chain & Critical Path Analysis
• Pricing Analysis
• Technology Analysis
• Patent Analysis
• Trade Analysis
• Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Viscosupplementation Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Viscosupplementation Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

KiOmed Pharma and Arsylab Announce Strategic Partnership for the Promotion and Distribution in France of KioMedinevsone, a New Class of Treatment for Refractory Knee Osteoarthritis

Kiomed Pharma and ARSYLAB have entered a strategic partnership to promote and distribute KIOMEDINEVS.ONE, a breakthrough treatment class for individuals suffering from refractory knee osteoarthritis in France. This innovative therapy represents a new direction in viscosupplementation, offering a promising option for patients.

Anika’s Cingal Successfully Achieves Primary Endpoint in Third Phase III Study

Anika Therapeutics completed a Phase 3 clinical trial for its innovative product, CINGAL. CINGAL is specifically formulated to provide effective treatment for the symptoms of osteoarthritis through intra-articular viscosupplementation. The primary endpoint of the study clearly demonstrated that a single intra-articular injection of CINGAL outperformed placebo in improving patient symptom scores at the 24-week mark.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Viscosupplementation Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Viscosupplementation Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alcon Inc., Anika Therapeutics, Inc., Avanos Medical, Inc., Bausch Health Companies Inc., Bioventus LLC, Contipro A.S., DePuy Synthes by Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Ferring B.V., Fidia Farmaceutici S.p.A., Gentex Pharma, LLC, LG Chem Ltd., Lifecore Biomedical, LLC, Quimfa S.A., Regen Lab SA, Sanofi S.A., Seikagaku Corporation, Smith & Nephew PLC, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zimmer Biomet.

Market Segmentation & Coverage

This research report categorizes the Viscosupplementation Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Product
• Five Injection
• Single Injection
• Three Injection
• Source
• Animal
• Non-animal
• Application
• Hand Osteoarthritis
• Hip Osteoarthritis
• Knee Osteoarthritis
• End-use
• Hospitals
• Orthopedic Clinics/Ambulatory Surgical Centers (ASCs)
• Region
• Americas
• Argentina
• Brazil
• Canada
• Mexico
• United States
• California
• Florida
• Illinois
• New York
• Ohio
• Pennsylvania
• Texas
• Asia-Pacific
• Australia
• China
• India
• Indonesia
• Japan
• Malaysia
• Philippines
• Singapore
• South Korea
• Taiwan
• Thailand
• Vietnam
• Europe, Middle East & Africa
• Denmark
• Egypt
• Finland
• France
• Germany
• Israel
• Italy
• Netherlands
• Nigeria
• Norway
• Poland
• Qatar
• Russia
• Saudi Arabia
• South Africa
• Spain
• Sweden
• Switzerland
• Turkey
• United Arab Emirates
• United Kingdom

Please Note: PDF & Excel + Online Access - 1 Year